42 results about "Hiv infected patients" patented technology

Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.

The invention relates to a compound composition of a traditional Chinese medicine, in particular to an anti-AIDS compound composition and a preparation method thereof. Pilos antler, wolfberry fruits, herba epimedii, rhizoma curculiginis, herba cistanches and other traditional Chinese raw materials are extracted, concentrated, decocted, filtered, concentrated, dried in vacuum, smashed and mixed to prepare the anti-AIDS compound composition. The compound composition is mainly used for treating AIDS patients and HIV-infected patients, and can restrain and kill AIDS virus improve the immunity of human bodies and increase the number of CD4 cells in human body, thereby eliminating all symptoms of patients and restoring the strength and weight of patients so that the patients can work and live healthily. The anti-AIDS compound composition is efficient and safe, causes no drug resistance and has no toxic side effects, no rebound after drug withdraw and wide application range. In addition, the anti-AIDS compound composition can be applied to children and pregnant women as well as all varieties and stages of HIV-infected patients.

This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.

The invention discloses a T cell comprising a chimeric antigen receptor (CAR) modification, a preparation or a medicine prepared from the T cells, the use of the T cells for preparing a cell drug, andthe preparation or the drug for treating and removing a cell storage bank of human immunodeficiency virus (HIV) in a HIV infected patient. The invention further discloses a cell immunotherapy using gp120 antibody CART, and specifically using 3BNC117 scFv-CART, which achieves MHC independent recognition and killing specific for HIV latent cells, so that the goal of eradicating AIDS is achieved.

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and / or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and / or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

The invention is a general method for improving the performance of the DNA-based vaccines. The method utilizes a complex DNA-generated profile of antigens to extend the effects of DNA-based vaccines and to broaden the immune response. This broadened immune response in turn improves the protection of the recipient from divergent (but related) strains of a pathogen. In addition, it effectively improves the efficacy of DNA-based vaccines used for treatment of viral diseases, including acquired immunity disorder (AIDS). One embodiment, where the target viral pathogen is HIV (the causative agent for aids), the method identifies an orderly set of plasmids of related sequences that may be used to prime a broad and strong immune response to HLA-restricted viral antigens. This mixture of plasmids is thus capable of priming an appropriate immune response to reduce the viral burden in HIV infected patients or to protect uninfected patients from HIV infection.

Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients.

This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.

Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD4+ T cells from peripheral blood mononuclear cells isolated from human subjects in the presence of an antiretroviral drug and for treating HIV infection by infusing the expanded CD4+ cells into HIV-infected patients.

Use of an extract of animal, plant or microorganism produced origin comprising docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal. Said treatment is effective and overcomes the disadvantages of current lipodystrophy treatments in HIV infected patients.

A method of identifying at least one CTL-inducing epitope from HIV protein is disclosed. In one embodiment, the method comprises the steps of (a) examining the nucleic acid sequence encoding at least one HIV protein from at least one HIV-infected patient, wherein the sequence encoding the expressed protein is examined in the first six months after infection, to identify at least one region of the HIV protein that is variable as compared to the sequence of the protein at an earlier time point in infection, wherein the variable region indicates a CTL-inducing epitope, and (b) confirming that an immune response directed against the CTL-inducing epitope is capable of selecting for viral escape variants during the acute or periacute phase of HIV infection is of high avidity.

A new antiviral water-soluble pharmacological product with anti-HIV effect, is based on ionic silver and methylene blue compound. The new substance is produced in the form of water-soluble powder that can be used for the preparation of finished dosage forms for treating viral infections, especially HIV infection. The product has a potential ability to radically suppress the infectious agents without leading to any mutations and resistance of viruses. The composition of the new product proposed under the conventional name Argothiazin-A™ corresponds to the chemical formula: C20H24AgN3O4S.

The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and / or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.

Use of an extract of animal, plant or microorganism-produced origin comprising docosahexaenoic acid as active substance for the manufacture of a medicament for the treatment of lipodystrophy in a mammal. The medicament is administered to a patient who is concomitantly receiving a highly active anti-retroviral therapy (HAART). The treatment is effective and overcomes the disadvantages of current lipodystrophy treatments in HIV-infected patients.